Benzamide, heteroarylamide and reverse amides
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to novel to P2X7 inhibitors of formula I
and to processes for their preparation, intermediates useful in their preparation, pharmaceutical compositions containing them, and their use in therapy. The active compounds of the present invention are potent inhibitors of P2X7 and as such are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
-
Citations
56 Claims
-
1. A compound of the formula
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)
-
2. A compound according to claim 1 wherein X, Y and Z are ═
- (CR6)—
, ═
(CR7)—
, and ═
(CR8)—
respectively.
- (CR6)—
-
3. A compound according to claim 1 wherein X, Y and Z are ═
- (CR6)—
, ═
(CR7)—
, and ═
(CR8)—
, respectively; and
each of R6, R7, and R8 is hydrogen.
- (CR6)—
-
4. A compound according to claim 1 wherein X, Y and Z are ═
- N—
, ═
(CR7)—
, and ═
(CR8)—
respectively.
- N—
-
5. A compound according to claim 1 wherein X, Y and Z are ═
- (CR6)—
, ═
N—
, and ═
(CR8)—
respectively.
- (CR6)—
-
6. A compound according to claim 1 wherein X, Y and Z are ═
- (CR6)—
, ═
(CR7)—
, and ═
N—
respectively.
- (CR6)—
-
7. A compound according to claim 1 wherein X, Y and Z are ═
- N—
, ═
(CR7)—
, and ═
N—
respectively.
- N—
-
8. A compound according to claim 1 wherein X, Y and Z are ═
- (CR6)—
, ═
N—
, and ═
N—
respectively.
- (CR6)—
-
9. A compound according to claim 3, wherein A is —
- (C═
O)NH—
.
- (C═
-
10. A compound according to claim 3, wherein A is —
- NH(C═
O)—
.
- NH(C═
-
11. A compound according to claim 9, wherein R3 is (C4-C10)alkyl.
-
12. A compound according to claim 9, wherein R3 is (C4-C10)alkyl substituted with one to three substituents independently selected from halo, hydroxy, —
- CN, (C1-C4)alkyl, (C1-C4)alkoxy, —
CF3, CF3O—
, (C1-C4)alkyl-S—
, (C1-C4)alkyl-(S═
O)—
, (C1-C4)alkyl-(SO2)—
, (C1-C4)alkyl-O—
(C═
O)—
, formyl, and (C1-C4)alkyl-(C═
O)—
.
- CN, (C1-C4)alkyl, (C1-C4)alkoxy, —
-
13. A compound according to claim 9, wherein R3 is (C3-C12)cycloalkyl-(CR11R12)s—
- wherein R11 and R12 are each independently hydrogen or (C1-C4)alkyl.
-
14. A compound according to claim 9, wherein R3 is (C3-C12)cycloalkyl-(CR11R12)s—
- wherein at least one of R11 and R12 is other than hydrogen or (C1-C4)alkyl.
-
15. A compound according to claim 9, wherein R3 is (C3-C12)cycloalkyl-(CR11R12)s—
- ;
optionally substituted by one to three substituents independently selected from the group consisting of hydrogen, halo, hydroxy, —
CN, (C1-C4)alkyl, (C1-C4)alkoxy, oxo, —
CO2-(C1-C4)alkyl, formyl, (C1-C4)alkyl-(C═
O)—
.
- ;
-
16. A compound according to claim 9, wherein R3 is (C3-C12)cycloalkyl-(CR11R12)s—
- optionally substituted by one to three substituents independently selected from the group consisting of hydrogen, halo, hydroxy, —
CN, (C1-C4)alkyl and (C1-C4)alkoxy.
- optionally substituted by one to three substituents independently selected from the group consisting of hydrogen, halo, hydroxy, —
-
17. A compound according to claim 9, wherein R3 is (C3-C12)cycloalkyl-(CR11R12)s—
- optionally substituted by at least one substituent selected from the group consisting of (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C6-C10)aryl-O—
, (C3-C8)cycloalkyl-O—
, (C1-C10)heteroaryl-O— and
(C1-C10)heterocyclyl-O—
;
wherein each of the aforesaid (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl and (C1-C10)heterocyclyl anywhere on said (C3-C12)cycloalkyl-(CR11R12)s—
substituents may optionally be substituted by one to three moieties per ring, independently selected from the group consisting of halo, hydroxy, —
CN, (C1-C4)alkyl, (C1-C4)alkoxy, —
CF3, CF3O—
, (C1-C4)alkyl-S—
, (C1-C4)alkyl-(S═
O)—
, (C1-C4)alkyl-(SO2)—
, —
CO2-(C0-C4)alkyl, formyl, and (C1-C4)alkyl-(C═
O)—
.
- optionally substituted by at least one substituent selected from the group consisting of (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C6-C10)aryl-O—
-
18. A compound according to claim 9, wherein R3 is (C3-C12)cycloalkyl-(CR11R12)s—
- optionally substituted by at least one spiro substituent selected from the group consisting of (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C6-C10)aryl-O—
, (C3-C8)cycloalkyl-O—
, (C1-C10)heteroaryl-O— and
(C1-C10)heterocyclyl-O—
;
wherein each of the aforesaid (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl and (C1-C10)heterocyclyl spiro substituent on said (C3-C12)cycloalkyl-(CR11R12)s—
may optionally be substituted by one to three moieties per ring, independently selected from the group consisting of halo, hydroxy, —
CN, (C1-C4)alkyl, (C1-C4)alkoxy, —
CF3, CF3O—
, (C1-C4)alkyl-S—
, (C1-C4)alkyl-(S═
O)—
, (C1-C4)alkyl-(SO2)—
, —
CO2-(C1-C4)alkyl, formyl, and (C1-C4)alkyl-(C═
O)—
.
- optionally substituted by at least one spiro substituent selected from the group consisting of (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C6-C10)aryl-O—
-
19. A compound according to claim 9, wherein R3 is (C6-C10)aryl-(CR11R12)q—
- (CH2)—
;
wherein R11 and R12 are each independently hydrogen or (C1-C4)alkyl.
- (CH2)—
-
20. A compound according to claim 9, wherein R3 is (C6-C10)aryl-(CR11R12)q—
- (CH2)—
;
wherein R11 and R12 are each independently selected from the group consisting of hydrogen and (C1-C4)alkyl and wherein each of R11 and R12 of the CR11R12 directly attached to group A are hydrogen; and
wherein said (C6-C10)aryl of said (C6-C10)aryl-(CR11R12)q—
(CH2)—
group member is substituted by one to three substituents independently selected from the group consisting of hydrogen, halo, hydroxy, —
CN, (C1-C4)alkyl, (C1-C4)alkoxy, oxo, (C1-C4)alkyl-O—
(C═
O)—
, formyl, benzyloxy and (C1-C4)alkyl-(C═
O)—
.
- (CH2)—
-
21. A compound according to claim 9, wherein R3 is (C6-C10)aryl-(CR11R12)q—
- (CH2)—
;
wherein R11 and R12 are each independently selected from the group consisting of hydrogen and (C1-C4)alkyl; and
wherein said (C6-C10)aryl of said (C6-C10)aryl-(CR11R1R2)q—
(CH2)—
group member is substituted by one to three substituents independently selected from the group consisting of hydrogen, halo, —
CN, (C1-C4)alkyl, benzyloxy and (C1-C4)alkoxy.
- (CH2)—
-
22. A compound according to claim 9, wherein R3 is (C6-C10)aryl-(CR1R12)q—
- (CH2)—
;
wherein R11 and R12 are each independently selected from the group consisting of hydrogen and (C1-C4)alkyl; and
wherein said (C6-C10)aryl of said (C6-C10)aryl-(CR11R12)q—
(CH2)—
group member is substituted by at least one substituent selected from the group consisting of (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C6-C10)aryl-O—
, (C3-C8)cycloalkyl-O—
, (C1-C10)heteroaryl-O— and
(C1-C10)heterocyclyl-O—
;
wherein each of the aforesaid (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl and (C1-C10)heterocyclyl substituents may optionally be substituted by one to three moieties per ring, independently selected from the group consisting of halo, hydroxy, —
CN, (C1-C4)alkyl, (C1-C4)alkoxy, —
CF3, CF3O—
, (C1-C4)alkyl-S—
, (C1-C4)alkyl-(S═
O)—
, (C1-C4)alkyl-(SO2)—
, (C1-C4)alkyl-O—
(C═
O)—
, formyl, benzyloxy and (C1-C4)alkyl-(C═
O)—
.
- (CH2)—
-
23. A compound according to claim 9, wherein R3 is (C1-C10)heteroaryl-(CR11R12)s—
- optionally substituted on any carbon atom able to support an additional substituent by one to three substituents per ring independently selected from the group consisting of halo, hydroxy, —
CN, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkyl-O—
(C═
O)—
, formyl, and (C1-C4)alkyl-(C═
O)—
.
- optionally substituted on any carbon atom able to support an additional substituent by one to three substituents per ring independently selected from the group consisting of halo, hydroxy, —
-
24. A compound according to claim 9, wherein R3 is (C1-C10)heteroaryl-(CR11R12)s—
- optionally substituted on any carbon atom able to support an additional substituent by one to three substituents per ring independently selected from the group consisting of halo, —
CN, (C1-C4)alkyl, (C1-C4)alkoxy, formyl, and (C1-C4)alkyl-(C═
O)—
.
- optionally substituted on any carbon atom able to support an additional substituent by one to three substituents per ring independently selected from the group consisting of halo, —
-
25. A compound according to claim 9, wherein R3 is (C1-C10)heteroaryl-(CR11R12)s—
- optionally substituted on at least one carbon atom able to support an additional substituent by a substituent selected from the group consisting of (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C6-C10)aryl-O—
, (C3-C8)cycloalkyl-O—
, (C1-C10)heteroaryl-O— and
(C1-C10)heterocyclyl-O—
;
wherein the aforesaid (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C6-C10)aryl-O—
, (C3-C8)cycloalkyl-O—
, (C1-C10)heteroaryl-O— and
(C1-C10)heterocyclyl-O—
substituents may optionally be substituted on any ring carbon atom by one to three moieties per ring, independently selected from the group consisting of halo, hydroxy, —
CN, (C1-C4)alkyl, (C1-C4)alkoxy, —
CF3, CF3O—
, (C1-C4)alkyl-S-, (C1-C4)alkyl-(S═
O)—
, (C1-C4)alkyl-(SO2)-, (C1-C4)alkyl-O—
(C═
O)—
, formyl, and (C1-C4)alkyl-(C═
O)—
.
- optionally substituted on at least one carbon atom able to support an additional substituent by a substituent selected from the group consisting of (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C6-C10)aryl-O—
-
26. A compound according to claim 9, wherein R3 is (C1-C10)heterocyclyl-(CR11R12)s—
- optionally substituted on any carbon atom able to support an additional substituent by one to three substituents per ring independently selected from the group consisting of halo, hydroxy, —
CN, (C1-C4)alkyl, (C1-C4)alkoxy, oxo, (C1-C4)alkyl-O—
(C═
O)—
, formyl, and (C1-C4)alkyl-(C═
O)—
.
- optionally substituted on any carbon atom able to support an additional substituent by one to three substituents per ring independently selected from the group consisting of halo, hydroxy, —
-
27. A compound according to claim 9, wherein R3 is (C1-C10)heterocyclyl-(CR11R12)s—
- optionally substituted on any carbon atom able to support an additional substituent by one to three substituents per ring independently selected from the group consisting of halo, —
CN, (C1-C4)alkyl, (C1-C4)alkoxy, oxo, formyl, and (C1-C4)alkyl-(C═
O)—
.
- optionally substituted on any carbon atom able to support an additional substituent by one to three substituents per ring independently selected from the group consisting of halo, —
-
28. A compound according to claim 9, wherein R3 is (C1-C10)heterocyclyl-(CR11R12)s—
- optionally substituted on at least one carbon atom able to support an additional substituent by a substituent selected from the group consisting of (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C6-C10)aryl-O—
, (C3-C8)cycloalkyl-O—
, (C1-C10)heteroaryl-o— and
(C1-C10)heterocyclyl-O—
;
wherein the aforesaid (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C1-C10)aryl-O—
, (C3-C8)cycloalkyl-O—
, (C1-C10)heteroaryl-O— and
(C1-C10)heterocyclyl-O—
substituents may optionally be substituted on any ring carbon atom by one to three moieties per ring, independently selected from the group consisting of halo, hydroxy, —
CN, (C1-C4)alkyl, (C1-C4)alkoxy, —
CF3, CF3O—
, (C1-C4)alkyl-S—
, (C1-C4)alkyl-(S═
O)—
, (C1-C4)alkyl-(SO2)—
, (C1-C4)alkyl-O—
(C═
O)—
, formyl, and (C1-C4)alkyl-(C═
O)—
.
- optionally substituted on at least one carbon atom able to support an additional substituent by a substituent selected from the group consisting of (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C6-C10)aryl-O—
-
29. A compound according to claim 9, wherein R3 is (C1-C10)heterocyclyl-(CR11R12)s—
- optionally substituted on at least one carbon atom able to support an additional substituent by a spiro substituent selected from the group consisting of (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C6-C10)aryl-O—
, (C3-C8)cycloalkyl-O—
, (C1-C10)heteroaryl-O— and
(C1-C10)heterocyclyl-O—
;
wherein the aforesaid (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C6-C10)aryl-O—
, (C3-C8)cycloalkyl-O—
, (C1-C10)heteroaryl-O— and
(C1-C10)heterocyclyl-O—
spiro substituents may optionally be substituted on any ring carbon atom by one to three moieties per ring, independently selected from the group consisting of halo, hydroxy, —
CN, (C1-C4)alkyl, (C1-C4)alkoxy, —
CF3, CF3O—
, (C1-C4)alkyl-S—
, (C1-C4)alkyl-(S═
O)—
, (C1-C4)alkyl-(SO2)—
, (C1-C4)alkyl-O—
(C═
O)—
, formyl, and (C1-C4)alkyl-(C═
O)—
.
- optionally substituted on at least one carbon atom able to support an additional substituent by a spiro substituent selected from the group consisting of (C6-C10)aryl, (C3-C8)cycloalkyl, (C1-C10)heteroaryl, (C1-C10)heterocyclyl, (C6-C10)aryl-O—
-
30. A compound according to claim 3, wherein R2 is chloro or bromo.
-
31. A compound according to claim 3, wherein R2 is chloro.
-
32. A compound according to claim 3, wherein R2 is (C1-C4)alkyl or —
- CN.
-
33. A compound according to claim 3, wherein R2 is hydroxy.
-
34. A compound according to claim 1, wherein R7 is other than hydrogen.
-
35. A compound according to claim 3, wherein R1 is optionally substituted (C1-C10)heterocyclyl selected from the group consisting of
-
36. A compound according to claim 3, wherein R1 is optionally substituted (C1-C10)heterocyclyl selected from the group consisting of
-
37. A compound according to claim 3, wherein R1 is optionally substituted (C1-C10)heterocyclyl selected from the group consisting of
-
38. A compound according to claim 3, wherein R1 is optionally substituted (C1-C10)heterocyclyl selected from the group consisting of
-
39. A compound according to claim 3, wherein R1 is optionally substituted (C1-C10)heterocyclyl selected from the group consisting of
-
40. A compound according to claim 3, wherein R1 is optionally substituted (C1-C10)heterocyclyl selected from the group consisting of
-
41. A compound according to claim 3, wherein R1 is optionally substituted (C1-C10)heterocyclyl selected from the group consisting of
-
42. A compound according to claim 3, wherein R1 is optionally substituted (C1-C10)heterocyclyl selected from the group consisting of
-
43. A compound according to claim 3, wherein R1 is optionally substituted (C1-C10)heterocyclyl selected from the group consisting of
-
44. A compound according to claim 3, wherein R1 is optionally substituted (C1-C10)heterocyclyl selected from the group consisting of
-
45. A compound according to claim 3, wherein R1 is selected from the group
-
46. A compound according to claim 3, wherein R1 is
-
47. A compound according to claim 1, wherein said compound of formula I has the formula
-
48. A compound according to claim 1 wherein said compound of formula I has the formula
-
49. A compound according to claim 1 wherein said compound of formula I has the formula
-
50. A compound according to claim 1, wherein said compound is selected from the group consisting of:
-
2-Chloro-N-[2-(2-chloro-phenyl)-ethyl]-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-benzamide;
2-Chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-N-[2-(2-fluoro-phenyl)-ethyl]-benzamide;
2-Chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-N-(2,2-diphenyl-ethyl)-benzamide;
N-[2-(2-Chloro-phenyl)-ethyl]-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-2-methyl-benzamide;
N-[2-(2-Benzyloxy-phenyl)-ethyl]-2-chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-benzamide;
2-Chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-N-(1-phenyl-cyclohexylmethyl)-benzamide;
2-Chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-N-(1-p-tolyl-cyclohexylmethyl)-benzamide;
2-Chloro-N-[2-(2-chloro-phenyl)-ethyl]-5-(4-methy1-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-benzamide;
2-Chloro-5-(3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-N-[2-(2-trifluoromethyl-phenyl)-ethyl]-benzamide; and
2-Chloro-N-[2-(2-chloro-phenyl)-ethyl]-5-(3-oxo-2,3-dihydro-benzo[1,4]thiazin-4-yl)-benzamide.
-
-
51. A method for treating a P2X7 mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to claim 1.
-
52. A method for treating a condition selected from the group consisting of arthritis inflammatory bowel disease, Crohn'"'"'s disease, emphysema, acute respiratory distress syndrome, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, allergic reactions, allergic contact hypersensitivity, eczema, contact dermatitis, psoriasis, sunburn, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, bone resorption disease, loosening of artificial joint implants, atherosclerosis, aortic aneurysm, congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, neurotrauma, spinal cord injury, neuro-degenerative disorders, Alzheimer'"'"'s disease, Parkinson'"'"'s disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, corneal scarring, scleritis, abnormal wound healing, burns, autoimmune disorders, Huntington'"'"'s disease, diabetes, AIDS, cachexia, sepsis, septic shock, endotoxic shock, conjunctivitis shock, gram negative sepsis, toxic shock syndrome, cerebral malaria, cardiac and renal reperfusion injury, thrombosis, glomerularonephritis, graft vs. host reaction, allograft rejection, organ transplant toxicity, ulcerative colitis, and muscle degeneration, in a mammal, including a human, comprising administering to said mammal an amount of a compound according to claim 1, effective in treating such a condition.
-
53. A pharmaceutical composition for the treatment of a P2X7 mediated disease in a mammal which comprises an effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
-
54. A pharmaceutical composition for the treatment of a condition selected from the group consisting of arthritis, inflammatory bowel disease, Crohn'"'"'s disease, emphysema, acute respiratory distress syndrome, adult respiratory distress syndrome, asthma, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, allergic reactions, allergic contact hypersensitivity, eczema, contact dermatitis, psoriasis, sunburn, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, osteoporosis, bone resorption disease, loosening of artificial joint implants, atherosclerosis, aortic aneurysm, congestive heart failure, myocardial infarction, stroke, cerebral ischemia, head trauma, neurotrauma, spinal cord injury, neuro-degenerative disorders, Alzheimer'"'"'s disease, Parkinson'"'"'s disease, migraine, depression, peripheral neuropathy, pain, cerebral amyloid angiopathy, nootropic or cognition enhancement, amyotrophic lateral sclerosis, multiple sclerosis, ocular angiogenesis, corneal injury, macular degeneration, corneal scarring, scleritis, abnormal wound healing, burns, autoimmune disorders, Huntington'"'"'s disease, diabetes, AIDS, cachexia, sepsis, septic shock, endotoxic shock, conjunctivitis shock, gram negative sepsis, toxic shock syndrome, cerebral malaria, cardiac and renal reperfusion injury, thrombosis, glomerularonephritis, graft vs. host reaction, allograft rejection, organ transplant toxicity, ulcerative colitis, and muscle degeneration in a mammal, including a human, comprising an amount of a compound according to claim 1, effective in treating such a condition and a pharmaceutically acceptable carrier.
-
2. A compound according to claim 1 wherein X, Y and Z are ═
-
55. A compound of the formula
-
56. A compound of the formula
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeZOETIS LLC (Zoetis Incorporated)
-
Original AssigneePfizer Inc.
-
InventorsSubramanyam, Chakrapani, Duplantier, Allen J.
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/242
-
CPC Class CodesA61P 1/02 Stomatological preparations...A61P 1/04 for ulcers, gastritis or re...A61P 11/00 Drugs for disorders of the ...A61P 11/06 AntiasthmaticsA61P 13/12 of the kidneysA61P 17/02 for treating wounds, ulcers...A61P 17/06 AntipsoriaticsA61P 19/02 for joint disorders, e.g. a...A61P 19/06 Antigout agents, e.g. antih...A61P 19/10 for osteoporosisA61P 21/04 for myasthenia gravisA61P 25/00 Drugs for disorders of the ...A61P 25/02 for peripheral neuropathiesA61P 25/06 Antimigraine agentsA61P 25/14 for treating abnormal movem...A61P 25/16 Anti-Parkinson drugsA61P 25/24 AntidepressantsA61P 25/28 for treating neurodegenerat...A61P 27/02 Ophthalmic agentsA61P 29/00 Non-central analgesic, anti...A61P 3/10 : for hyperglycaemia, e.g. an...A61P 31/00 : Antiinfectives, i.e. antibi...A61P 31/04 : Antibacterial agentsA61P 31/18 : for HIVA61P 33/06 : AntimalarialsA61P 35/00 : Antineoplastic agentsA61P 35/04 : specific for metastasisA61P 37/04 : ImmunostimulantsA61P 37/06 : Immunosuppressants, e.g. dr...A61P 37/08 : Antiallergic agents antiast...A61P 43/00 : Drugs for specific purposes...A61P 7/00 : Drugs for disorders of the ...A61P 7/02 : Antithrombotic agents; Anti...A61P 9/00 : Drugs for disorders of the ...A61P 9/04 : Inotropic agents, i.e. stim...A61P 9/08 : Vasodilators for multiple i...A61P 9/10 : for treating ischaemic or a...C07D 211/76 : attached in position 2 or 6C07D 213/64 : attached in position 2 or 6C07D 241/08 : with oxygen atoms directly ...C07D 249/12 : Oxygen or sulfur atomsC07D 263/24 : with hydrocarbon radicals, ...C07D 279/16 : condensed with one six-memb...C07D 405/12 : linked by a chain containin...C07D 409/12 : linked by a chain containin...